--- title: "藥明康德在第一季度業績強勁後股價上漲" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/284315901.md" description: "藥明康德的股價在強勁的第一季度財報發佈後上漲超過 17%，在香港上市的股票達到 148.00 港元。公司的淨利潤增長了 27%，達到 46.5 億元人民幣，收入增長了 29%，達到 124.4 億元人民幣，這得益於臨牀和商業項目的增加。分析師對這一結果持積極態度，認為這可能會導致增長指引的改善。上海上市的股票也上漲了 10%，創下自 2024 年 10 月以來的最大漲幅" datetime: "2026-04-28T05:25:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284315901.md) - [en](https://longbridge.com/en/news/284315901.md) - [zh-HK](https://longbridge.com/zh-HK/news/284315901.md) --- # 藥明康德在第一季度業績強勁後股價上漲 By Jason Chau Shares of Chinese pharmaceutical major WuXi AppTec gained after its strong first-quarter earnings. The company's Hong Kong-listed stock climbed over 17% to 148.00 Hong Kong dollars, equivalent to US$18.88, Tuesday morning before trimming some gains. Shares were up 15% at midday, reaching their highest level since December 2021 and on track for the largest single-day gain in 18 months. Its Shanghai-listed stock also rose 10% in the morning session, marking its largest daily gain since Oct 2024. The company's first-quarter net profit rose 27% on year to 4.65 billion yuan, it said in an exchange filing Monday. First-quarter revenue also jumped 29% on year to 12.44 billion yuan. The drugmaker attributed the sharp earnings growth to an increase in clinical and commercial projects, which improved capacity utilization, as well as efforts to optimize production processes. The company also cited its continued focus on strengthening its contract research, development, and manufacturing organization business model as a driver of sustained revenue growth, with rising order backlog reflecting growing customer demand. "We view the quarterly results as quite robust," Nomura analyst Jialin Zhang said in a note. The quarterly results and backlog orders on hand "bode well for the company to achieve or even lift topline growth guidance," Zhang said. Write to Jason Chau at jason.chau@wsj.com (END) Dow Jones Newswires April 28, 2026 01:18 ET (05:18 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [603259.CN](https://longbridge.com/zh-HK/quote/603259.CN.md) - [02359.HK](https://longbridge.com/zh-HK/quote/02359.HK.md) ## 相關資訊與研究 - [《大手成交》藥明康德一手約 64 萬股交叉盤，涉資 8865 萬元](https://longbridge.com/zh-HK/news/284489193.md) - [《外資精點》高盛上調藥明康德目標價至 169.4 元，維持「買入」評級](https://longbridge.com/zh-HK/news/284479626.md) - [《外資精點》摩通上調藥明康德目標價至 172 元，維持「增持」評級](https://longbridge.com/zh-HK/news/284479850.md) - [專家股份策略追蹤｜看好長飛光纖光纜 6869 續有資金追捧 推介藥明康德 2359](https://longbridge.com/zh-HK/news/284702135.md) - [藥明康德上季盈利按年升近 27%](https://longbridge.com/zh-HK/news/284192440.md)